ArticleFrontiers in endocrinology2025
Ghrelin's potential as a therapeutic target for chronic inflammatory diseases: evidence from human endometrial stromal cells.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ghrelin, a peptide composed of 28 amino acids, is recognized for its role in regulating appetite and energy balance. Recently, it has also been identified as an immunomodulator that could significantly influence immune responses in chronic inflammatory conditions. The role of ghrelin on cell viability and cytokine expression is presented here for human endometrial stromal (hEM15A) cells, with attention to the way this peptide could modulate inflammation. Methods: In this study, the hEM15A cells were cultured and treated with Ghrelin at concentrations ranging from 1 μM to 1000 μM. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. Levels of the cytokines TNF-α, IL-6, and IL-10 were measured by ELISA, and the expression of the Ghrelin receptor was confirmed through Western blot (WB) analysis. Results: The results demonstrated successful expression of the Ghrelin receptor (GHSR) in hEM15A cells. Analysis of cell viability indicated that Ghrelin positively affected cell proliferation, particularly at higher concentrations. ELISA results showed a significant decrease in pro-inflammatory cytokines TNF-α and IL-6, coupled with a notable increase in the anti-inflammatory cytokine IL-10, in a dose-dependent manner. Conclusion: Ghrelin can exert its effects through its receptor GHSR. Meanwhile, Ghrelin stimulates cell growth without causing decrease in viability; it has cell protective effect by regulating inflammation at the molecular level by balancing the release of some key pro-inflammatory cytokines. This study discovered and validated the anti-inflammatory effect of Ghrelin in patients with endometriosis. Thus, the data presented open a potential use of Ghrelin as therapy for chronic inflammation-related disorders as endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.